MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
Triple Helix: Global Regional Innovation Clusters (RICs)
*Triple Helix Cluster & Developments: North America
*Triple Helix Cluster & Developments: U.S.
*Triple Helix Cluster & Developments: Connecticut
Industry: Connecticut
Gennao Bio, Inc.
Parents
*Architects: Biotechnology _Monoclonal, Polyclonal, Bispecific Antibodies & Antibody-Drug Conjugates (ADC)s
*Architects: Drug Delivery
Industry: Connecticut
Children
2021: Gennao Bio Closes $40 Million Series A Financing to Develop
2021: The Series A financing was co-led by OrbiMed and Logos Capital, with participation by Surveyor Capital (a Citadel company).
Co-founders Peter Glazer, M.D., Ph.D., Elias Quijano, M. Phil., Stephen Squinto, Ph.D. and Bruce Turner, M.D., Ph.D.
Founded 2020
GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells.
New Haven, Connecticut
Proprietary, first-in-class gene monoclonal antibody platform (GMAB), exclusively licensed from Yale University, and the development of targeted nucleic acid therapeutic product candidates for the treatment of oncology and rare monogenic skeletal muscle diseases.
Jumps
Yale University